Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report

Table 1 Main differences between RECIST 1.1 and ir-RECIST, adapted from Wang et al[21]

	Progression	New measurable lesion	New non measurable lesion
RECIST 1.1	Increase in tumor burden on one examination	Represent progressive disease	Follow-up necessary
Ir- RECIST	Increase in tumor burden on two examinations > 4 wk apart	Are incorporated into tumor burden	Preclude complete response

RECIST: Response evaluation criteria in solid tumors.